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2nd
generation
DES
1st
generation
DES BMS p-value
Diabetes mellitus 57(53.3%) 68(48.9%) 19(36.5%) 0.14
ACS presentation 56(52.8%) 81(58.3%) 28(53.9%) 0.67
Duration from stent
implantation (yrs)
1.10.8 3.32.1 5.85.6 <0.001
Total stent length (mm) 32.218.7 29.416.1 21.813.5 0.001
Average reference lumen
area (mm2)
6.41.9 6.31.8 6.32.3 0.99
Minimum lumen area
(MLA) (mm2)
2.60.7 2.50.8 2.70.7 0.25
Minimum stent area (MSA) 4.71.6 4.91.6 6.42.2 <0.001
MSA <5mm2 69.2% 56.8% 28.8% <0.001
%NIH at MLA site 52.316.9 56.116.0 60.912.8 0.006
Diffuse ISR 28.0% 30.2% 28.8% 0.01
Stent fracture, n (%) 8.3% 5.8% 0.0% 0.10
Stent malapposition, n (%) 10.3% 10.1% 7.7% 0.86
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: Although the mechanisms of restenosis seem to be similar between 1st
and 2nd generation DES, restenotic DES were characterized by more co-existent
mechanical complications (underexpansion and strut fracture) and less neointimal
hyperplasia than restenotic BMS.
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Background: Additional placement of limus stents (Sirolimus-eluting stent [SES] or
Everolimus-eluting stents [EES]) for the treatment of in-stent restenosis of SES (SES-
ISR) has been a matter of controversy. This prompted us to assess the clinical out-
comes of additional limus-stent in patients presenting with SES-ISR comparing with
balloon angioplasty (BA).
Methods: Enrollment included patients with SES-ISR undergoing repeat target lesion
revascularization (TLR). The patients were grouped according to treatment into EES,
SES and BA groups. The end points were a comparison of major adverse cardiac
events (MACE) composed by all-cause mortality, myocardial infarction and TLR, as
well as incidence of deﬁnite stent thrombosis (ST).
Results: Overall, 310 patients with SES-ISR were treated with [EES (n¼43), SES
(n¼102) and BA (n¼165)]. The baseline characteristics were similar among the
3 groups. The incidence of 1-year MACE was similar among the 3 groups (14.6%,
18%, 20%; respectively; p¼0.72). The incidence of ST was 0% in all the groups.
When the restenotic lesions were classiﬁed into the ﬁrst ISR versus recurrent ISR,
MACE-free rate for recurrent ISR was signiﬁcantly lower when compared with the
ﬁrst ISR for the entire cohort. (67.4% vs 83.8%; p¼0.006) (Figure). This was also
observed in the limus-stent treatment group (66.7% vs 85.5%; p¼0.029).Conclusions: The outcome of patients treated for SES-ISR is similar among ﬁrst- or
second-generation DES and BA. Patients with recurrent ISR are doing poorly even
with second-generation limus-stent.B192 JACC Vol 64/11/Suppl B j SeptembeTCT-660
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Background: Little is known about the effect of sirolimus-eluting stent (SES) im-
plantation in in-stent restenosis (ISR) lesion more than ﬁve years. We aimed to
compare the clinical outcomes up to nine years after the ﬁrst SES implantation be-
tween in ISR lesion and in de novo lesion.
Methods: A total of 395 patients underwent the ﬁrst SES implantation between
November 2002 and December 2004. There were 139 patients for ISR lesion and 256
patients for de novo lesion. We evaluated stent thrombosis (ST) and target lesion
revascularization (TLR) from the SES implantation to ﬁve years and beyond ﬁve
years. ST was deﬁned deﬁnite ST according to the Academic Research Consortium
deﬁnition.
Results: Complete nine-year follow-up was achieved in 91.9% (363/395). The cumu-
lative incidences of nine-year ST were 5.6% in the ISR group and 2.3% in the de novo
group (p¼0.17): TLR, 45.6% and 20.2% (p< 0.001) respectively. As the ﬁgure shows,
the TLR rate in ISR group was signiﬁcantly higher than in de novo group through nine
years, and the difference of the TLR rate in two groups increased in this period.Conclusions: The incidence of TLR after the SES implantation in ISR lesion was
signiﬁcantly higher than that in de novo lesion and the difference of the TLR rate
between in two lesions became more clear through nine years, although the incidence
of ST had no signiﬁcant difference in two lesions.
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Background: Clinical trials have shown a short term beneﬁt of drug eluting stents
(DES) compared to vascular brachytherapy (VBT) for the treatment of in-stent
restenosis (ISR). The long term beneﬁts of DES vs. VBT are conﬂicting in the
literature. This study aimed to do a meta-analysis of long term outcomes of DES
compared to VBT for treatment of ISR.
Methods: PubMed, EMBASE, Cochrane Central and unpublished data were searched
for cohort studies and randomized controlled trials (RCTs) that directly compared
VBT to DES for the treatment of ISR. We evaluated outcomes at 2 to 5 years of follow
up. Random-effects model was used for calculation of odds ratio (OR).
Results:We included 1,364 patients from 5 studies, of which 3 were RCTs. VBT was
used to treat ISR in 677 (49.6%) patients. After a 2 to 5 year follow up, no signiﬁcant
difference was found between treatment groups regarding myocardial infarction
(p¼0.50), stent thrombosis (p¼0.88), cardiovascular mortality (p¼0.35) and overall
mortality (p¼0.72). Target lesion revascularization (TLR; OR 2.39; CI 1.56-3.68;
p< 0.001) and target vessel revascularization (TVR; OR 2.27; CI 1.02-5.21; p¼0.04)
were signiﬁcantly increased in patients who received VBT. As illustrated in ﬁgure 1,
subanalysis including only RCTs showed consistent long-term beneﬁt of DES over
VBT for TLR (p¼0.01) and TVR (p¼0.04).r 13–17, 2014 j TCT Abstracts/Coronary Lesions - In-stent Restenosis
